세계의 인간 마이크로바이옴 시장 : 제품 유형별, 용도별, 적응증별, 유통 채널별, 지역별
Human Microbiome Market, By Product Type, Application, Disease Indication (Auto Immune Disorder, Clostridium Difficile Infection, Metabolic Disorder, Inflammatory Bowel disorder, Infectious Diseases, & Others), Distribution Channel, & Geography
상품코드
:
1357952
리서치사
:
Coherent Market Insights
발행일
:
2023년 09월
페이지 정보
:
영문
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
세계 휴먼 마이크로바이옴 시장은 2023년 6억 1,790만 달러에 달할 것으로 추정되며, 예측 기간(2023-2030년) 동안 24.6%의 CAGR을 나타낼 것으로 예상됩니다.
| 보고 대상 범위 |
보고서 상세 |
| 기준년도 |
2022년 |
2023년 시장 규모 |
6억 1,790만 달러 |
| 실적 데이터 |
2018년-2021년 |
예측 기간 |
2023-2030 |
| 예측 기간의 CAGR |
24.60% |
2030년 시장 규모 전망 |
28억 8,450만 달러 |
인간 마이크로바이옴 세계 시장 점유율(%), 제품 유형별, 2023년
인간 마이크로바이옴은 인간 안팎에 존재하는 모든 미생물을 의미하며, 인간의 메타게놈에 기여하는 미생물 유전체의 집합체입니다. 인간의 마이크로바이옴은 인간의 장내 세균을 중심으로 10조에서 100조 개의 공생 미생물 세포로 구성되어 있습니다. 나이, 영양상태, 생활습관, 호르몬 변화, 유전적 유전자 및 기저질환은 인간 마이크로바이옴의 주요 결정요인이며, 마이크로바이옴의 변화나 균형이 깨지면 암, 장내 염증성 질환, 심혈관 질환, 항생제 내성으로 인한 치료하기 어려운 세균 감염 등 생명에 위협적인 질병을 유발할 수 있습니다. 미생물총의 역할은 음식물 소화를 촉진하고, 면역 체계를 조절하며, 비타민 K, 비타민 B, 비타민 B12와 같은 비타민을 생산하며, 2022년 8월에 발행된 마이크로바이오테크놀로지 저널에 발표된 논문에 따르면 조직의 면역 반응은 미생물군집 구성에 의해 조절됩니다. 에 의해 조절되며, 각 조직은 마이크로바이옴 구성을 다르게 만드는 고유한 미세 환경을 가지고 있으며, 특히 유방암, 대장암, 신장암, 폐암, 피부암 등 다양한 유형의 암과 관련하여 마이크로바이옴 구성을 다르게 만듭니다. 이 때문에 마이크로바이옴 산업의 주요 기업들은 연구와 조사에 집중하고 있습니다.
시장 역학
마이크로바이옴 산업의 주요 기업들은 메타게놈, 전사체학 등 새로운 분자 기술 연구 및 개발에 주력하고 있습니다. 최근 영양실조 연구와 감염성 질환의 발전은 암, 위장관의 만성 염증, CVD, 불안과 우울증 등 세계 건강의 가장 큰 문제를 해결하기 위한 마이크로바이옴 기반 전략의 잠재력을 확립하고 있습니다. 예를 들어, 2023년 4월 마이크로바이옴 치료제를 개발하는 세레스 테라퓨틱스(Ceres Therapeutics)는 재발성 CDI에 대한 항균제 치료 후 성인의 C. difficile 감염 재발을 예방하기 위한 최초의 경구용 마이크로바이옴 치료제인 'VOWSTT'를 미국 미국 식품의약국(FDA)으로부터 승인을 받았습니다. 이처럼 현재 진행 중인 인간 마이크로바이옴 분야의 연구개발은 제약사들에게 다양한 희귀질환 치료에 관여하는 혁신적인 의약품과 치료법을 개발할 수 있는 기회를 제공합니다.
본 조사의 주요 특징
- 이 보고서는 세계 휴먼 마이크로바이옴 시장을 상세하게 분석하고 2022년을 기준연도로 하여 예측 기간(2023년-2030년) 시장 규모와 연평균 성장률(CAGR)을 제공합니다. 다양한 부문의 잠재적 수익 기회를 파악하고 이 시장의 매력적인 투자 제안 매트릭스를 설명합니다.
- 또한 시장 성장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업이 채택한 경쟁 전략 등에 대한 중요한 고찰을 제공합니다.
- 이 보고서는 기업 하이라이트, 제품 포트폴리오, 주요 하이라이트, 성과 및 전략과 같은 매개 변수를 기반으로 세계 휴먼 마이크로바이옴 시장의 주요 기업을 프로파일링합니다.
- 이 보고서의 통찰력을 통해 마케팅 담당자와 기업 경영진은 향후 제품 출시, 유형화, 시장 확대 및 마케팅 전략에 대한 정보에 입각한 의사결정을 내릴 수 있습니다.
- 인간 마이크로바이옴 세계 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 시장 진출기업, 재무 분석가 등 이 산업의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자는 세계 휴먼 마이크로바이옴 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 용이하게 할 수 있습니다.
목차
제1장 조사 목적과 전제
제2장 시장 전망
제3장 시장 역학, 규제, 동향 분석
- 시장 역학
- 영향 분석
- 최근 테스트 발사
- 역학
- 합병, 인수 및 협업
- 규제 시나리오
- 주요 발전
- PEST 분석
제4장 세계의 인간 마이크로바이옴 시 장 -COVID-19의 영향 분석
- 경제적 영향
- 신형 코로나바이러스(COVID-19) 역학
- 수요 및 공급에 대한 영향
제5장 세계의 인간 마이크로바이옴 시장, 제품 유형별, 2018-2030년
- 식품
- 마이크로바이옴 약제
- 분변 미생물총 이식
- 기타(공생 물질, 항생제 등)
제6장 세계의 인간 마이크로바이옴 시장, 용도별, 2018년부터 2030년
제7장 세계의 인간 마이크로바이옴 시장, 적응 질환별, 2018-2030년
- 자가면역질환
- 클로스트리듐 디피실 감염증
- 대사장애
- 염증성장질환
- 감염증
- 기타(암, 희귀질환)
제8장 세계의 인간 마이크로바이옴 시장, 유통 채널별, 2018-2030년
제9장 세계의 인간 마이크로바이옴 시장, 지역별, 2018년부터 2030년
- 북미
- 유럽
- 아시아태평양
- 라틴아메리카
- 중동
- 아프리카
제10장 경쟁 구도
- 기업 개요
- Seres Therapeutics
- BIOMESENSE
- Microbiotica
- Vedanta Biosciences, Inc.
- SECOND GENOME THERAPEUTICS
- Finch Therapeutics Group, Inc
- Enterome
- BiomX
- MaaT Pharma
- Azitra
- Illumina, Inc
- Locus Biosciences, Inc
- Finch Therapeutics Group, Inc
- Rebiotix Inc
- Servatus Ltd
- Microbiome Research Pvt. Ltd
- AOBiome
- Axial Therapeutics, Inc
- Biomica.
제11장 섹션
LSH
영문 목차
Global human microbiome market is estimated to be valued at US$ 617.9 Mn in 2023, and is expected to exhibit a CAGR of 24.6% during the forecast period (2023-2030).
| Report Coverage |
Report Details |
| Base Year: |
2022 |
Market Size in 2023: |
US$ 617.9 Mn |
| Historical Data for: |
2018 to 2021 |
Forecast Period: |
2023 - 2030 |
| Forecast Period 2023 to 2030 CAGR: |
24.60% |
2030 Value Projection: |
US$ 2,884.5 Mn |
Global Human Microbiome Market Share (%), By Product Type, 2023
Human microbiome are the full range of microorganisms that are present inside and outside the Humans, It is collection of microbial genomes that contribute to metagenome, of a human. The human micro biota consists of the 10-100 trillion symbiotic microbial cells primarily bacteria in the gut the human. The age, nutrition, lifestyle, hormonal changes, inherited genes, and underlying disease are major determinants of the human microbiome, and any change or in balance in microbiota can cause life threatening illness such as cancer, bowel inflammatory disease, cardiovascular disease, and difficult-to-treat bacterial infections due to antibiotic resistance. Their roles ranges from enabling easy digestion of food, regulation of immune system, and production of vitamins such as Vitamin K, Vitamin B, and Vitamin B12. According to the article published published by journal of microbial biotechnology, published on August 2022, tissue immune responses are regulated by their microbiome composition, and each tissue has their specific microenvironment that makes their microbiome composition different, particularly in the context of different types of cancer, such as breast, colorectal, kidney, lung, and skin. Herein, key players in the microbiome industry are focusing on researches and studies.
Market Dynamics
The key players in the microbiome industry are focusing on researches and development of new molecular technologies such as metagenomics, transcriptomics. Recent advances in malnutrition research and infectious disease have established the potential for microbiome-based strategies to address the biggest challenges in global health including cancer, chronic inflammation in GIT, CVD, anxiety and depression, and others. For instance, in April 2023, Seres Therapeutics, a microbiome therapeutics company that developsbiological drugs, received the U.S. food and Drug Administration approval for it's first orally administered microbiome therapeutic drug named 'VOWSTT' for prevention of recurrence of C. difficile infection in adults following antibacterial treatment for recurrent CDI. Thus, the ongoing research and development in the field of human microbiome offer opportunities for the pharmaceutical companies to develop more innovative drugs or therapies that are involved to treat various range of rare diseases.
Key features of the study:
- This report provides an in-depth analysis of the global human microbiomes market and provides market size (US$ Million) and compound annual growth rate (CAGR) for the forecast period (2023-2030), considering 2022 as the base year It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global human microbiomes market based on the following parameters- company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this study include Seres Therapeutics, BIOMESENSE, Microbiotica, Vedanta Biosciences, Inc., SECOND Seres Therapeutics, Biomesense, Microbiotica, Infant Bacterial Therapeutics AB, Vedanta Biosciences, Inc., Second genome therapeutics, 4D Pharma Ferring Inc, Enterome, BiomX, MaaT Pharma, Azitra, Illumina, Inc, Locus Biosciences, Inc, Finch Therapeutics Group, Inc, Rebiotix Inc, Servatus Ltd, Microbiome Research Pvt. Ltd, AOBiome, Axial Therapeutics, Inc, Biomica
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- Global human microbiomes market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global human microbiomes market
Detailed Segmentation:
- Global Human Microbiomes Market, By Product Type:
- Food
- Probiotics
- Prebiotics
- Medical Food Supplements
- Microbiome Drugs
- Fecal Microbiota Transplant
- Others (Symbiotic, Antibiotics, etc.)
- Global Human Microbiome Market, By Application:
- Therapeutics
- Diagnostics
- Nutrition and Deities
- Others (Cosmetics, Animal health etc. )
- Global Human Microbiome Market, By Disease Indication:
- Auto Immune Disorder
- Clostridium Difficile Infection
- Metabolic Disorder
- Inflammatory Bowel disorder
- Infectious Diseases
- Others (Cancer, Rare Diseases)
- Global Human Microbiome Market, By Disribution Channel:
- Hospital
- Retail Pharmacies
- Online Pharmacies
- Global Human Microbiome Market, By Region:
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East
- Africa
- Company Profiles
- Seres Therapeutics
- Biomesense
- Microbiotica
- Infant Bacterial Therapeutics AB
- Vedanta Biosciences, Inc.
- SECOND GENOME THERAPEUTICS
- Finch Therapeutics Group, Inc
- Enterome
- BiomX
- MaaT Pharma
- Azitra
- Illumina, Inc
- Locus Biosciences, Inc
- Finch Therapeutics Group, Inc
- Rebiotix Inc
- Servatus Ltd
- Microbiome Research Pvt. Ltd
- AOBiome
- Axial Therapeutics, Inc
- Biomica
Table of Contents
1. Research Objective and Assumption
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Product Type
- Market Snippet, By Disease Indication
- Market Snippet, By Application
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Recent Test Launches
- Epidemiology
- Merger, Acquisition, and Collaborations
- Regulatory Scenario
- Key Developments
- PEST Analysis
4. Global Human Microbiome Market- COVID-19 Impact Analysis
- Economic Impact
- COVID-19 Epidemiology
- Impact on Supply and Demand
5. Global Human Microbiome Market, By Product Type, 2018- 2030, (US$ Bn)
- Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018 - 2030
- Segment Trends
- Food
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
- Segment Trends
- Probiotics
- Prebiotics
- Medical Food Supplements
- Microbiome Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
- Segment Trends
- Fecal Microbiota Transplant
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
- Segment Trends
- Others (Symbiotic, Antibiotics, etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
- Segment Trends
6. Global Human Microbiome Market, By Application, 2018 - 2030, (US$ Bn)
- Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018 - 2030
- Segment Trends
- Therapeutics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
- Segment Trends
- Diagnostics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
- Segment Trends
- Nutrition and Deities
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
- Segment Trends
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
7. Global Human Microbiome Market, By Disease Indication, 2018 - 2030, (US$ Bn)
- Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018 - 2030
- Segment Trends
- Auto Immune Disorder
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
- Segment Trends
- Clostridium Difficile Infection
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
- Segment Trends
- Metabolic Disorder
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
- Segment Trends
- Inflammatory Bowel Disorder
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
- Segment Trends
- Infectious Diseases
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
- Segment Trends
- Others (Cancer, Rare Diseases)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
- Segment Trends
8. Global Human Microbiome Market, By Distribution Channel, 2018 - 2030, (US$ Bn)
- Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018 - 2030
- Segment Trends
- Hospital
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
9. Global Human Microbiome Market, By Region, 2018 - 2030, (US$ Bn)
- Introduction
- Market Share Analysis, By Region, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, For Region, 2018 - 2030
- Segment Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2018 -2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2018 -2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2018 -2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 -2030, (US$ Bn)
- U.S.
- Canada
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2018 -2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2018 -2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2018 -2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 -2030, (US$ Bn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2018 -2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2018 -2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2018 -2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 -2030, (US$ Bn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2018 -2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2018 -2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2018 -2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 -2030, (US$ Bn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2018 -2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2018 -2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2018 -2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 -2030, (US$ Bn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2018 -2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2018 -2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2018 -2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 -2030, (US$ Bn)
- North Africa
- Central Africa
- South Africa
10. Competitive Landscape
- Company Profiles
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- BIOMESENSE
- Microbiotica
- Vedanta Biosciences, Inc.
- SECOND GENOME THERAPEUTICS
- Finch Therapeutics Group, Inc
- Enterome
- BiomX
- MaaT Pharma
- Azitra
- Illumina, Inc
- Locus Biosciences, Inc
- Finch Therapeutics Group, Inc
- Rebiotix Inc
- Servatus Ltd
- Microbiome Research Pvt. Ltd
- AOBiome
- Axial Therapeutics, Inc
- Biomica.
11. Section
- References
- Research Methodology
- About us and Sales Contact
관련자료
